Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) EBITDA Margin: 2020-2024

Historic EBITDA Margin for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to 14.47%.

  • Oncology Institute's EBITDA Margin rose 79000.0% to 5.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.05%, marking a year-over-year increase of 78900.0%. This contributed to the annual value of 14.47% for FY2024, which is 84000.0% up from last year.
  • Oncology Institute's EBITDA Margin amounted to 14.47% in FY2024, which was up 84000.0% from 22.87% recorded in FY2023.
  • Oncology Institute's 5-year EBITDA Margin high stood at 4.0% for FY2020, and its period low was 31.85% during FY2022.
  • Moreover, its 5-year median value for EBITDA Margin was 22.18% (2021), whereas its average is 19.08%.
  • Per our database at Business Quant, Oncology Institute's EBITDA Margin plummeted by -181800bps in 2021 and then surged by 89800bps in 2023.
  • Annual analysis of 5 years shows Oncology Institute's EBITDA Margin stood at 4.0% in 2020, then plummeted by -454bps to 22.18% in 2021, then tumbled by -44bps to 31.85% in 2022, then rose by 28bps to 22.87% in 2023, then surged by 37bps to 14.47% in 2024.
  • Its EBITDA Margin was 14.47% in FY2024, compared to 22.87% in FY2023 and 31.85% in FY2022.